X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs GLENMARK PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER GLENMARK PHARMA PFIZER/
GLENMARK PHARMA
 
P/E (TTM) x 31.2 12.2 256.0% View Chart
P/BV x 5.0 3.2 154.1% View Chart
Dividend Yield % 0.7 0.4 174.1%  

Financials

 PFIZER   GLENMARK PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-16
GLENMARK PHARMA
Mar-17
PFIZER/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,724993 274.3%   
Low Rs1,611729 220.9%   
Sales per share (Unadj.) Rs440.9325.5 135.4%  
Earnings per share (Unadj.) Rs48.739.3 123.9%  
Cash flow per share (Unadj.) Rs75.848.7 155.7%  
Dividends per share (Unadj.) Rs15.002.00 750.0%  
Dividend yield (eoy) %0.70.2 298.0%  
Book value per share (Unadj.) Rs462.9159.2 290.8%  
Shares outstanding (eoy) m45.75282.17 16.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.92.6 185.8%   
Avg P/E ratio x44.521.9 203.1%  
P/CF ratio (eoy) x28.617.7 161.7%  
Price / Book Value ratio x4.75.4 86.6%  
Dividend payout %30.85.1 605.2%   
Avg Mkt Cap Rs m99,163242,991 40.8%   
No. of employees `0002.913.0 22.3%   
Total wages/salary Rs m2,75816,408 16.8%   
Avg. sales/employee Rs Th6,981.77,083.9 98.6%   
Avg. wages/employee Rs Th954.51,265.4 75.4%   
Avg. net profit/employee Rs Th771.1855.1 90.2%   
INCOME DATA
Net Sales Rs m20,17091,857 22.0%  
Other income Rs m857374 229.5%   
Total revenues Rs m21,02892,230 22.8%   
Gross profit Rs m4,31020,367 21.2%  
Depreciation Rs m1,2392,644 46.9%   
Interest Rs m52,373 0.2%   
Profit before tax Rs m3,92315,724 25.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m99-810 -12.2%   
Tax Rs m1,7943,827 46.9%   
Profit after tax Rs m2,22811,088 20.1%  
Gross profit margin %21.422.2 96.4%  
Effective tax rate %45.724.3 187.9%   
Net profit margin %11.012.1 91.5%  
BALANCE SHEET DATA
Current assets Rs m16,29968,746 23.7%   
Current liabilities Rs m7,59427,027 28.1%   
Net working cap to sales %43.245.4 95.0%  
Current ratio x2.12.5 84.4%  
Inventory Days Days6585 76.8%  
Debtors Days Days2696 27.0%  
Net fixed assets Rs m8,62224,132 35.7%   
Share capital Rs m458282 162.1%   
"Free" reserves Rs m20,72244,643 46.4%   
Net worth Rs m21,18044,925 47.1%   
Long term debt Rs m2545,363 0.1%   
Total assets Rs m29,137117,639 24.8%  
Interest coverage x755.57.6 9,907.2%   
Debt to equity ratio x01.0 0.1%  
Sales to assets ratio x0.70.8 88.7%   
Return on assets %7.711.4 67.0%  
Return on equity %10.524.7 42.6%  
Return on capital %19.019.1 99.2%  
Exports to sales %0.10-   
Imports to sales %17.50-   
Exports (fob) Rs m12NA-   
Imports (cif) Rs m3,526NA-   
Fx inflow Rs m5256,152 0.1%   
Fx outflow Rs m1408,084 1.7%   
Net fx Rs m-8848,068 -0.2%   
CASH FLOW
From Operations Rs m3,4366,574 52.3%  
From Investments Rs m-6,991-7,124 98.1%  
From Financial Activity Rs m-6195,432 -11.4%  
Net Cashflow Rs m-4,1741,992 -209.5%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 6.9 108.7%  
FIIs % 4.9 34.4 14.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 10.5 225.7%  
Shareholders   85,207 56,727 150.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   CIPLA  SANOFI INDIA  ALKEM LABORATORIES  SHASUN PHARMA  PIRAMAL ENTERPRISES  

Compare PFIZER With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Feb 23, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS